HIV IN PATIENTS AND ANIMALS--CELL MEDIATED IMMUNITY AND VIRAL ISOLATION
HIV IN PATIENTS AND ANIMALS--CELL MEDIATED IMMUNITY AND VIRAL ISOLATION
批准号:
3804821
负责人:
M WELLS
金额:
$0.0万
依托单位:
--
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
中文摘要
点击翻译按钮获取中文摘要
英文摘要
We continued collaboration with Johns Hopkins Medical Center studying 5
new patients enrolled in the HIV bone marrow transplant study. Sequential
virus isolations were done on PBL isolated from these AIDS patients before
and after bone marrow transplantation. The patients cells were cultured
with normal human blast cells for 4 weeks, sampled weekly & tested for HIV
antigen. The following data summarizes the results through 11/90,
indicating that there is a trend towards virus reduction after
transplantation. The project was temporarily halted for reevaluation and
will be continued by Dr.Hana Golding in the Lab of DNA viruses.
Studies of the antibody and antigen status of Rhesus monkeys inoculated in
1987 with live HIV-1 virus continued to reveal no antigen being detected,
while antibody persisted in the 2 seropositive animals, though at lower
levels. A group of Rhesus inoculated in Sept 1988 were also followed
during this FY and results indicated that monkeys primed with a gp160
recombinant vaccinia to IIIB and RF viruses followed by 2 boosters with
purified gp160 remained seropositive through 95 weeks. A followup study
designed to evaluate whether inoculation of IIIB-recombinant vaccinia and
2 boosts with purified gp160 at 2 & 8 months, a different interval than
used with the first experiment would either reproduce or maximize the
response seen previously. Evaluation of sera through the 5th month
indicated that initial inoculation with the vaccinia recombinant induced
a better antibody response than initial inoculation with purified gp160.
Sequential bleeds from these animals are awaiting analysis.
Another study tested a new IIIB gp160 recombinant compared to that used in
previous studies and found no antibody response in 6 months when screened
on a standard ELISA. Subsequent screening using a purified gp160 ELISA as
well as ELISA's specific for antibodies to V3 peptides of IIIB, MN, SF2
and RF strains, indicated low level responses in some of the animals in
both groups by the 4th month.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HIV IN PATIENTS AND ANIMALS--CELL MEDIATED IMMUNITY AND VIRAL ISOLATION
-
批准号:3811262
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:M WELLS
-
依托单位:--
海外基金